These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28049400)

  • 21. Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase.
    Ahmed S; Khan ST; Zargaham MK; Khan AU; Khan S; Hussain A; Uddin J; Khan A; Al-Harrasi A
    Biomed Pharmacother; 2021 Jul; 139():111609. PubMed ID: 33915501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
    Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
    Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gene therapy and Alzheimer's disease].
    Li J; Li W; Zhou J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Apr; 40(4):428-32. PubMed ID: 25931222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intended pharmacotherapeutical approaches of Alzheimer's disease therapy].
    Korábecný J; Hrubá E; Soukup O; Zemek F; Musílek K; Nepovímová E; Spilovská K; Opletalová V; Kuca K
    Ceska Slov Farm; 2012 Feb; 61(1-2):4-10. PubMed ID: 22536646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug candidates in clinical trials for Alzheimer's disease.
    Hung SY; Fu WM
    J Biomed Sci; 2017 Jul; 24(1):47. PubMed ID: 28720101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z; Zhong C
    Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromones: privileged scaffolds for the production of multi-target-directed-ligand agents for the treatment of Alzheimer's disease.
    Silva CFM; Pinto DCGA; Silva AMS
    Expert Opin Drug Discov; 2018 Dec; 13(12):1141-1151. PubMed ID: 30430870
    [No Abstract]   [Full Text] [Related]  

  • 30. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].
    Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF
    Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anticholinesterases in the treatment of Alzheimer's disease].
    Gandía L; Alvarez RM; Hernández-Guijo JM; González-Rubio JM; de Pascual R; Rojo J; Tapia L
    Rev Neurol; 2006 Apr 16-30; 42(8):471-7. PubMed ID: 16625509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Alzheimer disease.
    Winslow BT; Onysko MK; Stob CM; Hazlewood KA
    Am Fam Physician; 2011 Jun; 83(12):1403-12. PubMed ID: 21671540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.
    Jabir NR; Khan FR; Tabrez S
    CNS Neurosci Ther; 2018 Sep; 24(9):753-762. PubMed ID: 29770579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of Successful Symptomatic Treatment in Parkinson's Disease for Therapeutic Strategies of Alzheimer's Disease.
    Zhao L; Cheng X; Zhong C
    ACS Chem Neurosci; 2019 Feb; 10(2):922-930. PubMed ID: 30474958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine.
    Nagakura A; Shitaka Y; Yarimizu J; Matsuoka N
    Eur J Pharmacol; 2013 Mar; 703(1-3):53-61. PubMed ID: 23276665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush.
    Rosini M; Simoni E; Bartolini M; Cavalli A; Ceccarini L; Pascu N; McClymont DW; Tarozzi A; Bolognesi ML; Minarini A; Tumiatti V; Andrisano V; Mellor IR; Melchiorre C
    J Med Chem; 2008 Aug; 51(15):4381-4. PubMed ID: 18605718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current pharmacotherapy for Alzheimer's disease.
    Lleó A; Greenberg SM; Growdon JH
    Annu Rev Med; 2006; 57():513-33. PubMed ID: 16409164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.
    Kroker KS; Moreth J; Kussmaul L; Rast G; Rosenbrock H
    Brain Res Bull; 2013 Jul; 96():28-38. PubMed ID: 23639920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.